Full archive
Pharmacogenomics
Week of 3 June 2026
7 articles
Geno'X Veille — genox-veille.fr
Key takeaways this week
- ►CYP2C19 — high prevalence of rapid/ultrarapid metabolizers in PPI-refractory GERD: genotyping as a second-line tool.
- ►DPYD — ultra-low-dose capecitabine documented in a DPYD*2A homozygous patient: pharmacokinetic guidance for a rare and lethal situation.
- ►TPMT/NUDT15 — international comparison of TDM + PGx guidelines for thiopurines in IBD: major divergences to harmonize.
Category:
Filters··Min. score
7 articles of 7
Sort
CYP2C19
PubMedHigh Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease.
Gastroesophageal reflux disease — PPI failure, CYP2C19 rapid/ultrarapid metabolizer prevalence
8
/10
CPIC Level ADose recommendation
Clin Gastroenterol Hepatol 2026· JunRead
DPYD
PubMedClinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance.
Complete DPD deficiency (DPYD*2A homozygous) — ultra-low-dose capecitabine
7
/10
OncologyCPIC Level AAdverse reaction
Br J Clin Pharmacol 2026· MayRead
CYP2C19
PubMedOptimizing P2Y12 Inhibitor Therapy in Post-PCI Patients Through Genotype-Guided Strategies: A Systematic Review and Meta-Analysis.
Post-PCI — CYP2C19 genotype-guided P2Y12 inhibitor therapy optimization
6
/10
CardiologyCPIC Level APreemptive genotyping
Cardiovasc Drugs Ther 2026· JunRead
TPMT
PubMedTherapeutic Drug Monitoring and Pharmacogenomics of Thiopurines in Inflammatory Bowel Disease: International Guidelines Revisited.
IBD — thiopurine monitoring, TPMT/NUDT15 PGx and therapeutic drug monitoring
6
/10
ImmunosuppressantsCPIC Level ANew recommendation
Ther Drug Monit 2026· JunRead
CYP2D6
PubMedAripiprazole and CYP2D6: A retrospective cohort study evaluating the impact of phenotype on metabolic abnormalities.
Aripiprazole — metabolic abnormalities by CYP2D6 phenotype and phenoconversion
6
/10
PsychiatryPhenoconversionAdverse reaction
Am J Health Syst Pharm 2026· MayRead
NAT2
PubMedAcetylation Variability in Elderly Tunisians: Implications for Isoniazid Dose Individualization.
Tuberculosis — NAT2 acetylation variability, isoniazid dose individualization in elderly patients
6
/10
Dose recommendationAdverse reaction
J Clin Pharmacol 2026· JunRead
CYP1A2
PubMedEffects of Repeated Smoking and Quitting Cigarettes on Plasma Concentrations of Clozapine and Its N-Desmethyl and N-Oxide Metabolites in a Japanese Patient With Schizophrenia.
Clozapine — CYP1A2 phenoconversion by smoking and smoking cessation
4
/10
PsychiatryPhenoconversionAdverse reaction
Neuropsychopharmacol Rep 2026· JunRead
References and sources
- CYP2C19 — Gastroesophageal reflux disease — PPI failure, CYP2C19 rapid/ultrarapid metabolizer prevalence. Clin Gastroenterol Hepatol 2026. PMID 41197932. Score 8/10. https://pubmed.ncbi.nlm.nih.gov/41197932/
- CYP2C19 — Post-PCI — CYP2C19 genotype-guided P2Y12 inhibitor therapy optimization. Cardiovasc Drugs Ther 2026. PMID 40788330. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/40788330/
- TPMT — IBD — thiopurine monitoring, TPMT/NUDT15 PGx and therapeutic drug monitoring. Ther Drug Monit 2026. PMID 40879507. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/40879507/
- CYP2D6 — Aripiprazole — metabolic abnormalities by CYP2D6 phenotype and phenoconversion. Am J Health Syst Pharm 2026. PMID 41364071. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/41364071/
- CYP1A2 — Clozapine — CYP1A2 phenoconversion by smoking and smoking cessation. Neuropsychopharmacol Rep 2026. PMID 41954161. Score 4/10. https://pubmed.ncbi.nlm.nih.gov/41954161/
- NAT2 — Tuberculosis — NAT2 acetylation variability, isoniazid dose individualization in elderly patients. J Clin Pharmacol 2026. PMID 42223414. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42223414/
- DPYD — Complete DPD deficiency (DPYD*2A homozygous) — ultra-low-dose capecitabine. Br J Clin Pharmacol 2026. PMID 41633578. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/41633578/